Progress in Developing Influenza Vaccines
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Influenza Virus Vaccines".
Deadline for manuscript submissions: closed (30 April 2023) | Viewed by 3363
Special Issue Editor
Interests: vaccines; influenza virus; adenovirus; HIV; vectored vaccines; virus–host interactions
Special Issue Information
Dear Colleagues,
Vaccination has been a powerful approach to protect hosts against viral infections, especially from developing severe symptoms, hospitalization and even death. Due to the outbreak of COVID-19 pandemic, vaccination becomes important, even necessary, for people to return to normal life worldwide. Compared to SARS-CoV-2, influenza virus, as our “old friend”, is still a significant pathogen in humans and animals that causes extensive morbidity and mortality. Although flu shots are available every year, the improvement of its effectiveness will be significantly beneficial to the public, especially to the immune-compromised populations.
This Special Issue aims to provide an overview of recent progress in developing influenza vaccines, which may improve the influenza vaccine design, development, production and administration in the future. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but not limited to) the following:
- Effectiveness and safety
- Novel technologies
- New targets/epitopes
- Novel delivery approaches
- Host response to vaccines
- Immune responses in vaccinated populations
- Vaccination in different age groups
- Computation and prediction
I look forward to receiving your contributions.
Dr. Xizhi (Johnny) Guo
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
